Salute e Benessere

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of…

BOSTON and LONDON, Sept.11, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a...
Nasdaq GlobeNewswire
11/09/2024

Global Health Exhibition Announces Opportunity for Healthcare Startups to secure…

Closely aligned with the Kingdom of Saudi Arabia's healthcare objectives including crisis response and health security, technological and digital transformation, public health and disease prevention and health innovation, Vision NextGen judges anticipate high demand to join a shortlist of 30 companies from an anticipated longlist of over 150 businesses. Six finalists drawn from the shortlist will present to the competition's expert judging panel live at the Exhibition on 23 October 2024. The…
PR Newswire
11/09/2024

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial…

Oslo, September 11, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial (NCT05344209) to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab or pembrolizumab as first-line...
Nasdaq GlobeNewswire
11/09/2024

Cell-Based Assays Market to Grow from USD 17.3B in 2024 to USD 24.3B by 2029 at…

Browse in-depth TOC on "Cell-Based Assays Market" Browse in-depth TOC on "Cell-Based Assays Market" 200 - Tables50 - Figures350 - Pages Market Segmentation by Offering The global cell-based assays market is categorized into consumables, instruments, software, and services. Among these, the services segment is projected to experience the highest CAGR during the forecast period. Increasingly, researchers and pharmaceutical companies are outsourcing aspects of their...
PR Newswire
11/09/2024

KFSHRC Announced a Strategic Partner for 2024 NYC C3 Summit Davos of Healthcare

RIYADH, Saudi Arabia, Sept.11, 2024(GLOBE NEWSWIRE) -- In a significant move to bolster its global presence, the King Faisal Specialist Hospital & Research Centre (KFSHRC) is set to join as a key partner in the 2024 NYC C3 Summit Davos of Healthcare, kicking off on Monday in New York City. Under the theme "Tech-Driven Healthcare Evolution & Breakthroughs: Addressing Future Global Challenges & Impact of Advanced Technologies," the summit will foster dialogue and...
Nasdaq GlobeNewswire
11/09/2024

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

This opportunity will be available to all potential investors including current shareholders of RENB.Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology for multi-omics and multi-modal data analysis, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes, beginning with cancer.“Newly raised...
Nasdaq GlobeNewswire
11/09/2024

Tinnitus Quest Launches to Find a Cure for Hearing Disorder Affecting Millions

Despite the prevalence and profound impact of tinnitus, no cure or effective treatment is available. Many sufferers are simply advised to "learn to live with it." "Tinnitus Quest believes this status quo is unacceptable," said Sven Köllmann, founder of Tinnitus Quest. "We are committed to changing the narrative by funding agile research, investigating new research questions that have not been asked before, aimed at silencing tinnitus once and for all." Despite the…
PR Newswire
11/09/2024

FLOWPHYSIX ANNOUNCES STRATEGIC PARTNERSHIP WITH 3COMMA FOR INTERNATIONAL…

3comma Managing Partner and former Vice President of International at Penumbra, Inc., Marc Paris believes the FLOWRUNNER System will make an immediate impact in the peripheral thrombectomy segment. "We can rapidly activate our established international commercial infrastructure to accelerate adoption of the FLOWRUNNER system. We are confident that FlowPhysix will be the next major disruptor in the global thrombectomy market and we are excited to be part of this endeavor," Paris said…
PR Newswire
11/09/2024

IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

Mr. Arbel retired as Deputy CEO from Leumi, Israel's largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business. Mr. Arbel retired as Deputy CEO...
PR Newswire
11/09/2024

Trading by management and close relations of management

Please read the full announcement in PDFAttachment 2024_35_Trading_By_Management
Nasdaq GlobeNewswire
11/09/2024

IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative…

Article highlights preclinical findings demonstrating ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity Data show superior killing potency of multiple myeloma tumor cells by ISB 2001 when compared to several approved bispecific therapies and combination of therapiesNEW YORK, Sept.11, 2024(GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage...
Nasdaq GlobeNewswire
11/09/2024

TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation

The Science Behind TCI's GLP-1 Formula The Science Behind TCI's GLP-1 Formula TCI leverages its proprietary Bio-Resource Data Mining technology, an AI-powered system that autonomously identifies potent natural compounds. Backed by in-vitro studies and human trials, TCI's GLP-1 formula has proven to be a game-changer in the health and wellness sector. The formula stimulates natural GLP-1 secretion, enhances fat metabolism, stabilizes blood glucose, and induces white fat browning—making it an...
PR Newswire
11/09/2024

Nomination Committee of AB SKF for the Annual General Meeting 2025

Marcus Wallenberg, FAM Philip Ahlgren, Cevian CapitalAnders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, andHans Stråberg, Chair of the Board Marcus Wallenberg, FAM Philip Ahlgren, Cevian Capital Anders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, and Hans Stråberg, Chair of the Board The Annual General Meeting of AB SKF will be held inGothenburgon Tuesday,1 April 2025. Shareholders who wish to submit proposals to the Nomination Committee, may contact the Chair of...
PR Newswire
11/09/2024

Inside information: Orion upgrades full-year outlook for 2024

ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion's product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year...
Nasdaq GlobeNewswire
11/09/2024

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera…

Targeted Alpha Therapy is a promising new cancer treatment approach that enables safe and effective delivery of radiation to the cancer cells by radioisotopes that emit highly energetic alpha particles. The radiation effect of the alpha particle is more localized compared to other approaches and as such can destroy the cancer cells to which it is attached without harming surrounding healthy tissue. The most promising alpha emitter for this approach is 225Ac. As a result, demand for 225Ac is…
PR Newswire
11/09/2024

Press Release: Dupixent phase 3 study confirms significant improvements in itch…

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placeboMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesData...
Nasdaq GlobeNewswire
11/09/2024

IBA's joint venture PanTera secures EUR 93 million in oversubscribed Series A…

Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% shareholding in PanTera and...
Nasdaq GlobeNewswire
11/09/2024

Press Release: Dupixent is the first and only biologic to achieve significant…

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyStudy met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placeboDupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent...
Nasdaq GlobeNewswire
11/09/2024

'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging…

Authors explain that small masses in the kidney are increasingly being detected incidentally when patients undergo abdominal imaging, often for other health conditions, contributing to "an era of gross overtreatment". Diagnosis and treatment are limited by current imaging techniques, and renal mass biopsy is invasive, which can often lead to complications. Up to 30% of patients undergo unnecessary surgery, removing masses that are later determined to be benign[4]. If confirmed…
PR Newswire
11/09/2024

Global Respiratory Monitoring Devices Market to Register Sustainable Growth at a…

Key Takeaways from the Respiratory Monitoring Devices Market Report Key Takeaways from the Respiratory Monitoring Devices Market Report To read more about the latest highlights related to the respiratory monitoring devices market, get a snapshot of the key highlights entailed in theGlobal Respiratory Monitoring Devices Market Report Respiratory Monitoring Devices Overview Respiratory monitoring devices play a critical role in assessing and managing patients' respiratory...
PR Newswire
10/09/2024

BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight

Key Takeaways from the BTK Inhibitors Market Report Key Takeaways from the BTK Inhibitors Market Report Discover which therapies are expected to grab the BTK inhibitors market share @BTK Inhibitors Market Report BTK Inhibitors Market Dynamics The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is theincreasing incidence of cancerssuch...
PR Newswire
10/09/2024

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 10, 2024 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:4,623 shares at DKK 1,025.00, 3,656 shares at DKK 1,032.00, 561 shares at DKK 1,050.00, 1,645...
Nasdaq GlobeNewswire
10/09/2024

Sectra's Annual General Meeting 2024--resolution passed on share redemption…

It will be possible to trade in Class B redemption shares (ISIN: SE…) on Nasdaq Stockholm. It will be possible to trade in Class B redemption shares (ISIN: SE…) on Nasdaq Stockholm. Timetable for the redemption procedure: For information about the redemption procedure, visithttps://investor.sectra.com/redemption2024. Performance based incentive program LTIP 2024The AGM resolved on a long-term performance-based incentive program, LTIP 2024, which is to apply to a maximum of...
PR Newswire
10/09/2024

Bioinformatics Market to Reach $31.71 Billion by 2031, Driven by Growing…

Download FREE PDF Brochure Of Bioinformatics Market:- https://www.meticulousresearch.com/download-sample-report/cp_id=5731 Download FREE PDF Brochure Of Bioinformatics Market:- https://www.meticulousresearch.com/download-sample-report/cp_id=5731 The growth of the biotechnology & pharmaceutical industries, initiatives supporting genomics research, and the rising need to develop novel drugs/drug molecules are key factors driving the growth of the bioinformatics market. However, the...
PR Newswire
10/09/2024
Altri  Comunicati